PT Kimia Farma Tbk together with RSUPN Dr. Cipto Mangunkusumo (RSCM) and the Faculty of Medicine, University of Indonesia (FKUI) collaborate in research and production of stem cells and their derivatives to help treat the Indonesian people.
This stem cell development production facility has obtained a Good Manufacturing Practices (CPOB) certificate from the Food and Drug Supervisory Agency (BPOM). The CPOB certificate was presented directly by the Acting Head of BPOM RI at an event entitled "Harmony in Stem CelI" on July 25, 2024 at RSCM.
This facility is one of three stem cell facilities in Indonesia that has a CPOB certificate and the only facility that stands in a hospital.
Acting Head of BPOM Rizka Andalucia also congratulated Kimia Farma and RSCM on the issuance of the CPOB certificate from BPOM for the stem cell processing facility. CPOB certification is not just a facility, but also a guarantee of quality in every processing process in order to meet quality products with safety efficacy that has been proven in clinical trials. By obtaining CPOB, RSCM and Kimia Farma can process stem cell products not only for RSCM, but also for other hospitals.
President Director of RSCM, dr. Supriyanto, Sp.B, FINACS, M.Kes stated that, "The synergy between RSCM, Kimia Farma and FKUI will be even stronger with the acquisition of the CPOB certificate from BPOM for stem cell production facilities at RSCM. With one-stop service and a multidisciplinary team approach available, where RSCM also has a Stem Cell and Metabolites Clinic (SCMC) will guarantee comprehensive and integrative services by experienced doctors in their fields, starting from the diagnosis phase, treatment with stem cell implantation and its derivatives for various diseases to rehabilitation after implantation."
Innovation in the use of stem cells and their derivatives in treating diseases is currently very promising. Some diseases that can be treated using stem cells and their derivatives include osteoarthritis, Herniated Nucleus Pulposus (HNP), pneumonia, stroke, baldness, skin rejuvenation, melasma and others.
"Kimia Farma is committed to continuing to innovate in creating future treatments (advanced therapy medicinal products) that are greatly needed by the community. Collaboration between the Company and RSCM and FKUI researchers is expected to support the independence of domestic biological products," said Jasmine Karsono, Director of Portfolio, Products and Services at Kimia Farma.
In the future, the company will target stem cell products to obtain distribution permits from BPOM. This is a commitment from Kimia Farma and RSCM to the quality, safety, and quality of products according to applicable standards